logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis | Journal Article / Research | MSF Science Portal
Journal Article
|Research

First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis

Alikhanova N, Akhundova I, Seyfaddinova M, Mammadbayov E, Mirtskulava V, Rusch-Gerdes S, Bayramov R, Suleymanova J, Kremer K, Dadu A, Acosta CD, Harries AD, Dara M
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
SETTING
Civilian population of the Republic of Azerbaijan.

OBJECTIVES
To determine patterns of anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis (TB) cases, and explore their association with socio-demographic and clinical characteristics.

DESIGN
National cross-sectional survey conducted in 2012-2013.

RESULTS
Of 789 patients (549 new and 240 previously treated) who met the enrolment criteria, 231 (42%) new and 146 (61%) previously treated patients were resistant to any anti-tuberculosis drug; 72 (13%) new and 66 (28%) previously treated patients had multidrug-resistant TB (MDR-TB). Among MDR-TB cases, 38% of new and 46% of previously treated cases had pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. In previously treated cases, 51% of those who had failed treatment had MDR-TB, which was 15 times higher than in relapse cases (OR 15.2, 95%CI 6-39). The only characteristic significantly associated with MDR-TB was a history of previous treatment (OR 3.1, 95%CI 2.1-4.7); for this group, history of incarceration was an additional risk factor for MDR-TB (OR 2.8, 95%CI 1.1-7.4).

CONCLUSION
Azerbaijan remains a high MDR-TB burden country. There is a need to implement countrywide control and innovative measures to accelerate early diagnosis of drug resistance in individual patients, improve treatment adherence and strengthen routine surveillance of drug resistance.

Countries

Azerbaijan

Subject Area

antibiotic resistancetuberculosisSORT-ITantimicrobial resistance

Languages

English
DOI
10.5588/pha.14.0049
Published Date
21 Oct 2014
PubMed ID
26393092
Journal
Public Health Action
Volume | Issue | Pages
Volume 4, Issue 2, Pages S17-23
Issue Date
2014-10-21
Dimensions Badge